Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAMMA-1: Andecaliximab + mFOLFOX6 in Advanced Gastric/GEJ Adenocarcinoma
NCT02545504Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2015
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of andecaliximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Gilead Sciences. Started Oct 2015; status: completed.
02
Drugs
andecaliximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02545504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545504.